Anti-Obesity Medication (AOM) treatment

PreclinicalSmall molecule

Anti-Obesity Medication (AOM) treatment is one of 11 small molecule programs targeting Obesity & Overweight. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Obesity & OverweightNot yet recruiting

Obesity & OverweightPreclinical

Not yet recruiting

Competition

Competitive Landscape

13 competitors in Obesity & Overweight

#DrugCompanyPhaseTrials

Victoza

Novo Nordisk

Approved

1 2

Prilosec

DDexcel Pharma Technologies Ltd.

Approved

1 3

Ozempic

Novo Nordisk

Phase 2

2 4

Crestor

AstraZeneca

Preclinical

1 5

Semagludtide

Novo Nordisk

Phase 2

1 6

LUM-201

LLumos Pharma

Phase 2

1 7

Enobosarm

VVeru Inc.

Phase 2

1 8

Incretin-Based Treatment

JJohns Hopkins University

Preclinical

1 9

Spermidine

MMedical University of Graz

Preclinical

1 10

GLP-1 Receptor Agonist Therapy

GGazi University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

PreclinicalNot yet recruiting

Obesity & Overweight

NCT07728812

Q1 2030

Post-ApprovalNot yet recruiting

Atrial Fibrillation

NCT07027969

Clinical

Trials by Indication[1]

Atrial Fibrillation1 trial

Metabolic Surgery for Atrial Fibrillation Elimination

Not yet recruiting·AAli Aminian·Phase 4·NCT07027969·100 enrolled

Obesity & Overweight1 trial

Pragmatic Trial to Study the Cost-Effectiveness of MyPhenome-RX Test to Guide Anti-Obesity Pharmacotherapy (PhenoRX Pragmatic Trial)

Not yet recruiting·PPhenomix·Preclinical·NCT07728812·424 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Anti-Obesity Medication (AOM) treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Anti-Obesity Medication (AOM) treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Anti-Obesity Medication (AOM) treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ali Aminian company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AAli Aminian

Anti-Obesity Medication (AOM) treatment

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Q1 2030

Trials by Indication[1]

Atrial Fibrillation1 trial

Obesity & Overweight1 trial

References

Drug Info

Quick Facts

Related News